AstraZeneca Teams Up with PGA Golf Champion Jason Day to Raise Awareness about the Importance of Biomarker Testing in Lung Ca...
May 08 2019 - 7:00AM
Business Wire
Test It Back campaign encourages patients newly
diagnosed with non-small cell lung cancer to ensure they receive a
full diagnosis and the treatment that is right for them
AstraZeneca is teaming up with PGA golf champion Jason Day to
encourage newly diagnosed Stage IV non-small cell lung cancer
patients to ask their doctor about biomarker testing (sometimes
referred to as molecular testing or mutation testing), which can
help patients and their physician find the treatment options that
are right for them. AstraZeneca is partnering with the
world-renowned golf pro to launch the Test It Back campaign,
focused on ensuring complete biomarker testing becomes standard of
care at every late-stage lung cancer diagnosis. The Test It Back
site includes a series of inspiring videos featuring Day and his
mother, Dening, whose decision to get mutation testing of her Stage
IV non-small cell lung cancer last year informed her treatment
decisions.
Not all lung cancers are the same, and biomarker testing can
help determine which treatment options are right for specific types
of lung cancer. AstraZeneca and Jason Day are asking people to
visit TestItBack.com to learn more about the importance of
biomarker testing as part of a complete lung cancer diagnosis.
Doctors often test for biomarkers with a biopsy, using tissue
removed from a tumor or a patient’s blood sample.
Jason Day said: “My mother has always been the rock of our
family and she’s the reason I’m the player I am today. Her lung
cancer diagnosis was devastating, because you never think it will
happen to you or your family. I wanted her to have the best
possible care, and biomarker testing helped us understand our
treatment options. For anyone who is facing a lung cancer
diagnosis, I would encourage you to talk to your doctor about
biomarker testing. The test results can take some time but having
them really gives you a full picture of what you’re dealing
with.”
After testing her lung cancer for mutations, Dening Day learned
that her cancer had a mutation, which meant she was a candidate for
a targeted oral therapy that may help stop the cancer from growing
and spreading.
To learn more about biomarker testing and how it helps patients
understand more about their type of lung cancer, please visit
TestItBack.com.
NOTES TO EDITORS
About Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer death among both men
and women, accounting for about one-quarter of all cancer deaths in
the US, more than breast, prostate and colorectal cancers
combined.
About AstraZeneca in Lung Cancer
AstraZeneca is committed to developing medicines to help every
patient with lung cancer. We have three approved medicines and a
growing pipeline that targets genetic changes in tumor cells and
boosts the power of the immune response against cancer. Our
unrelenting pursuit of science aims to deliver more breakthrough
therapies with the goal of extending and improving the lives of
patients across all stages of disease and lines of therapy.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a
quickly growing portfolio of new medicines that has the potential
to transform patients' lives and the Company's future. With at
least six new medicines to be launched between 2014 and 2020, and a
broad pipeline of small molecules and biologics in development, we
are committed to advance Oncology as a key growth platform for
AstraZeneca focused on lung, ovarian, breast and blood cancers. In
addition to our core capabilities, we actively pursue innovative
partnerships and investments that accelerate the delivery of our
strategy, as illustrated by our investment in Acerta Pharma in
hematology.
By harnessing the power of four scientific platforms –
Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response
and Antibody Drug Conjugates – and by championing the development
of personalized combinations, AstraZeneca has the vision to
redefine cancer treatment and one day eliminate cancer as a cause
of death.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide. For more information, please visit
www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
US-28408 Last Updated 5/19
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190508005156/en/
Michele Meixell, +1 302 885 2677Stephanie Wiswall, +1 302 885
2677
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024